These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489 [TBL] [Abstract][Full Text] [Related]
5. Impact of Society Guidelines on Trends in Use of Newer P2Y Mohamed MO; Kontopantelis E; Alasnag M; Abid L; Banerjee A; Sharp ASP; Bourantas C; Sirker A; Curzen N; Mamas MA J Am Heart Assoc; 2024 May; 13(9):e034414. PubMed ID: 38700032 [TBL] [Abstract][Full Text] [Related]
6. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study. Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336 [TBL] [Abstract][Full Text] [Related]
7. Time-dependent benefits of pre-treatment with new oral P2Y Pepe M; Cafaro A; Paradies V; Signore N; Addabbo F; Bortone AS; Navarese EP; Contegiacomo G; Forleo C; Bartolomucci F; Di Cillo O; Bianchi FP; Zanna D; Favale S Catheter Cardiovasc Interv; 2019 Mar; 93(4):592-601. PubMed ID: 30269413 [TBL] [Abstract][Full Text] [Related]
8. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233 [TBL] [Abstract][Full Text] [Related]
10. Precatheterization Use of P2Y Badri M; Abdelbaky A; Li S; Chiswell K; Wang TY J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939715 [TBL] [Abstract][Full Text] [Related]
11. Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction. Beigel R; Mazin I; Koifman E; Shechter M; Pres H; Shlomo N; Rosenberg N; Asher E; Matetzky S J Thromb Haemost; 2018 Apr; 16(4):663-669. PubMed ID: 29443445 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study. Fanaroff AC; Kaltenbach LA; Peterson ED; Akhter MW; Effron MB; Henry TD; Wang TY J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437596 [TBL] [Abstract][Full Text] [Related]
13. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study. Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508 [TBL] [Abstract][Full Text] [Related]
14. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341 [TBL] [Abstract][Full Text] [Related]
15. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Jin C; Kim MH; Bang J; Serebruany V Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475 [TBL] [Abstract][Full Text] [Related]
17. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415 [TBL] [Abstract][Full Text] [Related]
18. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Pollack CV; Davoudi F; Diercks DB; Becker RC; James SK; Lim ST; Schulte PJ; Spinar J; Steg PG; Storey RF; Himmelmann A; Wallentin L; Cannon CP; Clin Cardiol; 2017 Jun; 40(6):390-398. PubMed ID: 28598510 [TBL] [Abstract][Full Text] [Related]